Jupiter Neurosciences, Inc. - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
JUNS Nasdaq 2840 jupiterneurosciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Jupiter Neurosciences, Inc.

Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Aug 31st, 2026 8:12 am
Real Parkinson’s Disease Hope from Jupiter Neurosciences - Aug 19th, 2026 10:32 am
Jupiter Neurosciences, Inc. Announces Reverse Stock Split - Aug 5th, 2026 6:00 am
Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva - Jul 22nd, 2026 11:25 am
Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS) - Jul 21st, 2026 8:27 am
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million - Jul 21st, 2026 5:13 am
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 - Jul 21st, 2026 5:00 am
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson - Jul 7th, 2026 6:58 am
Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream - Jun 9th, 2026 5:00 am
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering - May 26th, 2026 10:00 am
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering - May 20th, 2026 12:38 pm
PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF) - May 20th, 2026 9:12 am
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million - May 20th, 2026 6:15 am
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech - May 20th, 2026 5:38 am
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit - May 4th, 2026 9:30 am
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14 - Apr 13th, 2026 6:00 pm
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board - Apr 7th, 2026 6:00 am
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2 - Mar 31st, 2026 10:00 am
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Mar 13th, 2026 6:35 am